Amgen presents “encouraging” denosumab data

Amgen has announced “encouraging” results from a phase III trial into its denosumab product.

Dr David Henry, clinical professor of Medicine at Pennsylvania Hospital, made his remarks about the study, which evaluated the product administered subcutaneously against Zometa (zoledronic acid) in the treatment of bone metastases in advanced cancer patients.

The 1,776 participants either had multiple myeloma or solid tumours (not including prostate or breast cancer).

It was found that median time to the first on-study skeletal-related event was 20.6 months for people given denosumab compared to 16.3 months for those who received Zometa.

Dr Henry said: “It is encouraging to see denosumab’s efficacy in this broad cancer population. There is no need for renal monitoring or dose adjustments due to renal impairment.”

Amgen has presented at a number of events in recent weeks, including the Thomas Weisel Healthcare Conference, the Morgan Stanley Global Healthcare Unplugged Conference and the Baird Healthcare Conference.